http://www.the-infoshop.com/pharmaceutical.shtml Pharmaceutical Market Research Reports Global Information, Inc. (C) 2008 Global Information, Inc. 2009-11-20 daily en 2009-11-17 BioInformant http://www.the-infoshop.com/study/biof103549-cord-blood.html Over the past 12 months, the cord blood banking industry has expanded through double digit growth, due to new entrants in the cord blood banking industry as well as revenue growth at existing operations. Deeper analysis reveals that of existing cord blood banks, most fall into one of two camps, either experiencing flat-line growth (less than 3% per annum) or substantively building revenue (17% or more per annum). en 2009-11-17 Insight Pharma Reports http://www.the-infoshop.com/study/cd103562-inflam-disorder.html Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response reviews the problems of insuf-ficient efficacy, side effects, and adverse events associated with the small-molecule and biological drugs available today to treat these disorders. These observations have led to an interest in identifying ways to balance the immune reaction, to suppress the part of the immune response that is causing the disease, while maintaining or enhancing other aspects of the immune system. This report identifies nearly 400 ongoing product candidates and development programs in these indication areas. The companies active in these areas range from multinational pharmaceutical companies with a number of active programs to small boutique start-ups working on a very defined topic. en Cancer 2009-11-17 Datamonitor http://www.the-infoshop.com/study/dc103616-care-in-oncology.html Supportive care in oncology is defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies The supportive care market is potentially vast, therefore this report focuses on the cytopenias (anemia, neutropenia and thrombocytopenia), chemotherapy-induced nausea and vomiting, and bone metastases. en Pharmaceutical Companies 2009-11-16 Espicom Business Intelligence http://www.the-infoshop.com/study/es17140-novartis.html This report provides a full review of the company's activities together with sales forecasts for key products to 2010. en Pharmaceutical Companies 2009-11-16 Espicom Business Intelligence http://www.the-infoshop.com/study/es42295-eisai.html This report provides a full review of the company's activities together with sales forecasts for key products to 2010. en Infection Disease 2009-11-13 Frost & Sullivan http://www.the-infoshop.com/study/fs103523-tw-fungal-infect.html This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in Taiwan. en 2009-11-13 Frost & Sullivan http://www.the-infoshop.com/study/fs103524-us-overact-bladder.html This research service covers the U.S. overactive bladder market from 2005-2015. Included is a disease overview, product analysis, total market revenue forecasts, product revenue forecasts, patient forecasts and market share analysis. en 2009-11-12 Datamonitor http://www.the-infoshop.com/study/dc103420-healthc-pharma.html Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from 2011. Industry players are therefore looking to implement strategies which will cushion them against the anticipated revenue short-fall, with diversification away from pharmaceuticals into other healthcare sectors one avenue under consideration. en 2009-11-12 BioPharm Reports (Technology and Markets Ltd) http://www.the-infoshop.com/study/bph104174-hypertension.html This report presents the findings of a global survey on current treatments and prescribing practices for Hypertension. These findings were made following the participation of more than 280 clinics worldwide, which provided detailed information of their treatment practices. en 2009-11-10 Espicom Business Intelligence http://www.the-infoshop.com/study/es24091_pharmaceutical.html Based in New Jersey, Merck is a pharmaceutical products and services company with 34 manufacturing facilities worldwide in 17 different countries, including 16 distribution centres. en Pharmaceutical Companies 2009-11-10 Espicom Business Intelligence http://www.the-infoshop.com/study/es42303-takeda.html This report provides a full review of the company's activities together with sales forecasts for key products to 2010. en 2009-11-09 BCC Research http://www.the-infoshop.com/study/bc103308-antibiotic-techno.html The scope of this report includes current antibiotic markets as well as the emerging antibiotic market, with an exclusive focus on antibiotic resistance. It technically encompasses antibacterials that include antibiotics, bacterial vaccines, and other emerging antibacterials that are not necessarily classified as antibiotics. Prevention of bacterial infections using bacterial vaccines is within the scope of the study. Antiviral and antifungal products are excluded from the market definition, and vaccines targeting viral diseases are outside the scope of this study. In short, this report contains: Overview of antibiotic market Classification of bacteria Classification of antibiotics Mechanisms of resistance by bacteria Resistance trends and geographic analysis Antibiotics targeted to counter the resistance mechanisms Emerging regulatory trends Technology trends in combating resistance Patent analysis Current antibiotic market and future growth trends Emerging new approaches and product candidates in antibiotic resistance Analysis of leading companies and their strategies Sales projections through 2014 for antibiotic resistance markets The base year of this study is 2009. en 2009-11-09 Decision Resources, Inc. http://www.the-infoshop.com/study/dr103627-drug-price-debate.html The U.K. public' s suspicion of pharmaceutical profi teering in the H1N1 vaccine arena is just the tip of the iceberg in the ongoing and acrimonious battle over the prices that pharmaceutical companies charge for drugs and the costs that payers must cover to meet the increasing demands for healthcare. en Cancer 2009-11-05 Espicom Business Intelligence http://www.the-infoshop.com/study/es103264-prostate-cancer.html Prostate cancer (PCA) is the second leading cause of new cancer cases in men worldwide and the sixth leading cause of cancer death in men. In the US, over two million men currently suffer with PCA and it is estimated that there were 192,311 new cases and 29,698 deaths due to the disease in 2008. There have been dramatic improvements in PCA survival over the last 25 years, mainly due to a combination of earlier diagnosis and improvements in treatments, although rates vary between countries. en Infection Disease 2009-11-05 Frost & Sullivan http://www.the-infoshop.com/study/fs103315-fungal-infection.html This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in Singapore. en Infection Disease 2009-11-05 Frost & Sullivan http://www.the-infoshop.com/study/fs103319-au-fungal-infec.html This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in Australia. en Pharmaceutical Companies 2009-11-04 Business Insights http://www.the-infoshop.com/study/rb103176-cmo-market.html Falling productivity and patent expiries are placing increasing pressure on pharmaceutical companies to reduce fix costs including large manufacturing facilities. Sponsors are turning to CMOs in search of time and cost savings and as a way to flexibly manage outsourced manufacturing. Meanwhile the threat of overcapacity combined with inevitable program cancellations following mega-mergers resist the market. en Regulation 2009-11-04 Business Insights http://www.the-infoshop.com/study/rb103177-pharma-pricing.html Determining the correct pricing and reimbursement strategy for a new product is an essential component of gaining maximum return on investment. This report gives an up to date and comprehensive review of the pricing and reimbursement environment in the seven major pharmaceutical markets and also the four high-growth emerging markets, as well as providing analysis of the most likely future scenarios in these markets' pricing and reimbursement environments. en Pharmaceutical Companies 2009-11-04 Business Insights http://www.the-infoshop.com/study/rb103178-optimizing-lifecycle.html The need to derive the maximum commercial mileage from all components of a drug company' s portfolio is clearly evident in an era of falling returns on investment and higher capital costs. This report investigates three goals in optimizing product potential- expanding the drug' s patent protected lifespan, accessing broader patient populations and launching line-extensions via fixed dose combinations. en Pharmaceutical Companies 2009-11-04 Datamonitor http://www.the-infoshop.com/study/dc103617-les-laboratoire.html This analysis examines the historical and forecast performance for Servier in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en OTC Drug 2009-11-03 James Dudley International, Ltd. http://www.the-infoshop.com/study/jdi83657-otc-distribution-in-euro.html OTC Distribution in Europe 2010 edition is an in-depth strategic 18 country study. It defines and explores the main themes of change running through the European region and shows how they will influence the channel strategies for manufacturers' of non-prescription and OTC self-medication as well associated consumer healthcare products. en Pharmaceutical Companies 2009-11-03 Frost & Sullivan http://www.the-infoshop.com/study/fs103197-na-healthcare.html This research deliverable analyses the healthcare industry in Namibia by providing an overview of the total industry and a more in depth look at the medical devices and pharmaceutical industries. en Neurodegenerative Disease 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70919-neuroprotection.html This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many of the underlying mechanisms of damage to neural tissues are similar in all these conditions and several products are used in more than one disorder. en Drug Delivery System 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70921-transdermal.html This report deals with transdermal drug delivery - an approach used to deliver drugs through the skin for therapeutic use as an alternative to oral,intravascular, subcutaneous and transmucosal routes. Various transdermal drug delivery technologies are described including the use of suitable formulations, carriers and penetration enhancers. en 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70923-pain-therape.html This report describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain. Major segments of the pain market are arthritis, neuropathic pain and cancer pain. Because pain is a subjective sensation, it is difficult to evaluate objectively in clinical trials. Various tools for pain measurement are described, including brain imaging. en 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70925-nitric-oxide.html This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them. en Neurodegenerative Disease 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70927-alzheimer.html Alzheimer' s disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechanism of the disease and find a cure. en Drug Delivery System 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70928-drug-deli.html Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery for cancer. Cancer drug delivery is no longer simply wrapping up cancer drugs in a new formulations for different routes of delivery. The focus is on targeted cancer therapy. The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent damage to normal tissues and prevent drug resistance. en Neurodegenerative Disease 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70934-central-nervous.html The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders. Drugs may be administered directly into the CNS or administered systematically (e.g., by intravenous injection) for targeted action in the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance. en Drug Delivery System 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70936-cardiovascular.html Drug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients to all organs of the body. Drugs can be introduced into the vascular system for systemic effects or targeted to an organ via the regional blood supply. In addition to the usual formulations of drugs such as controlled release, devices are used as well. This report starts with an introduction to molecular cardiology and discusses its relationship to biotechnology and drug delivery systems. en Neurodegenerative Disease 2009-11-02 Decision Resources, Inc. http://www.the-infoshop.com/study/dr102700-neurologi-disease.html The plethora of recent reports of new genes and pathways linked to neurological diseases shows that the underlying causes of these diseases are far from certain; as a result, therapeutic strategies in effect today may soon be superseded by new approaches. en Vaccines 2009-11-02 Datamonitor http://www.the-infoshop.com/study/dc103026-vaccines-em-mkt.html Over the past decade, vaccines have resurfaced as an attractive commercial proposition for Pharma. The developed world has been the initial focus of vaccine makers due to the better healthcare infrastructure and higher price levels. en Pharmaceutical Companies 2009-11-02 Datamonitor http://www.the-infoshop.com/study/dc103028-king-pharma.html This analysis examines the historical and forecast performance for King in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en Infection Disease 2009-11-01 Markets and Markets http://www.the-infoshop.com/study/mama102658-h1n1vaccin.html H1N1 Influenza A (2009) is the first pandemic influenza of 21st century affecting more than more than four lac people in more than 180 countries across the globe in 2009. The flu broke in Mexico in the month of March and then affected U.S. and after that it spread across the globe. H1N1 (2009) influenza have a mutation of pig, bird and humans which has made it more dangerous and fatal compared to previous occurrence of H1N1 (1918). en Pharmaceutical Companies 2009-11-01 Aruvians Rsearch http://www.the-infoshop.com/study/aruv103561-pharma-ind-mexico.html Over the past decade, pharmaceutical companies have pushed the scientific envelope, working at the cellular and molecular levels to dramatically advance the treatment of disease. en Drug Discovery 2009-10-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es13861-glaxosmithkline.html This report provides a full review of the company' s activities together with sales forecasts for key products to 2010. en Pharmaceutical Companies 2009-10-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es22832_pharmaceutical.html AstraZeneca has corporate headquarters in London, and research and development headquarters in Sweden. It focuses on a number of therapeutic areas: gastrointestinal, respiratory, cardiovascular, pain control/anaesthesia, central nervous system, oncology and infection. en Pharmaceutical Companies 2009-10-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es25000_bayer_pharmaceutical.html The pharmaceuticals buisness group focuses on five major therapeutic categories; anti-infectives, cardiovasular, central nervous system, metabolics and oncology. en Pharmaceutical Companies 2009-10-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es42291-chugai.html This report provides a full review of the company's activities together with sales forecasts for key products to 2010. en Pharmaceutical Companies 2009-10-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es42293-daiichi-sankyo.html This report provides a full review of the company's activities together with sales forecasts for key products to 2010. en 2009-10-30 BCC Research http://www.the-infoshop.com/study/bc100149-preventi-healthc.html At the broadest level, preventive healthcare includes everything from over-the-counter (OTC) products designed to help users curb smoking or overeating to advanced genetic testing to identify a predisposition to certain cancers or other health problems. However, the scope of this report is limited to products that are available only by prescription, and related professional services that: Provide early warning of a disease before it becomes symptomatic. Identify a predisposition to disease or other health problem, so that appropriate steps can be taken (e.g., genetic screening for various cancers). Protect against or strengthen the body' s resistance to disease (e.g., vaccines). Reduce the possibility of unintended adverse impacts from therapy (e.g., adverse drug reactions). Are used in the management of chronic medical conditions. Some of these technologies, such as certain vaccines, are decades old, while others (e.g., cytomics) are still largely at the experimental stage for clinical applications. en 2009-10-30 BCC Research http://www.the-infoshop.com/study/bc100153-asthma-copd.html The report intends to provide a current market snapshot and future developments in the asthma and COPD drugs market over the period from 2007 through 2014. The report describes existing drug classes approved for these indications, such as bronchodilators, anti-inflammatory drugs, and combination drugs of inhaled corticosteroids and bronchodilators. The pipeline of drugs in clinical trials for these indications is also presented and analyzed. en OTC Drug 2009-10-30 Euromonitor International http://www.the-infoshop.com/study/eo103405-analgesics-denmark.html This report presents Analgesics in Denmark. en OTC Drug 2009-10-30 Euromonitor International http://www.the-infoshop.com/study/eo103406-remedies-denmark.html This report presents Cough, Cold And Allergy (Hay Fever) Remedies in Denmark. en OTC Drug 2009-10-30 Euromonitor International http://www.the-infoshop.com/study/eo103408-remedies-denmark.html This report presents Digestive Remedies in Denmark. en OTC Drug 2009-10-30 Euromonitor International http://www.the-infoshop.com/study/eo103430-aids-denmark.html This report presents NRT Smoking Cessation Aids in Denmark. en OTC Drug 2009-10-30 Euromonitor International http://www.the-infoshop.com/study/eo103435-eye-care-denmark.html This report presents Eye Care in Denmark. en OTC Drug 2009-10-30 Euromonitor International http://www.the-infoshop.com/study/eo103442-treatments-denmark.html This report presents Wound Treatments in Denmark. en Regulation 2009-10-29 Datamonitor http://www.the-infoshop.com/study/dc103029-id-ph-emerg-mkt.html As the developed markets are becoming increasingly mature, Pharma is turning to the emerging markets, where long-term growth can be sustained. Of particular interest are Indonesia and the Philippines, which are currently going through major reforms to expand their healthcare systems; however there are key differences between these two markets. en Drug Discovery 2009-10-29 BioSeeker Group AB http://www.the-infoshop.com/study/bg103311-protein-kinase.html This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target profiles, and assesses them in 57 different cancer indications. en 2009-10-28 Decision Resources, Inc. http://www.the-infoshop.com/study/dr102646-market-access-pricing.html The third quarter of 2009 saw a heated debate in the United States over healthcare reform, the publication of a report on a European investigation of the pharmaceutical industry, the election of new governments in Japan and Germany, and new initiatives by governments in other countries to control their national pharmaceutical spending. en Mental Disease 2009-10-28 Datamonitor http://www.the-infoshop.com/study/dc103030-antipsychotics.html In 2008, seven major market sales of antipsychotics reached $18.2 billion. Datamonitor forecasts the market value to peak in 2011 when it will then succumb to generic erosion, particularly in the US where incursion is the most rapid. However, the commercial opportunity still exists for developers who can differentiate their antipsychotics with reformulation and indication expansion strategies. en Infection Disease 2009-10-26 Frost & Sullivan http://www.the-infoshop.com/study/fs102574-hk-fung-infection.html This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in Hong Kong. en Infection Disease 2009-10-23 Frost & Sullivan http://www.the-infoshop.com/study/fs102575-ph-fung-infection.html This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in the Philippines. en Infection Disease 2009-10-23 Frost & Sullivan http://www.the-infoshop.com/study/fs102576-kr-fung-infection.html This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in South Korea. en Infection Disease 2009-10-22 Frost & Sullivan http://www.the-infoshop.com/study/fs102422-sys-fung-infection.html This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in Malaysia. en Pharmaceutical Companies 2009-10-21 BCC Research http://www.the-infoshop.com/study/bc102343-contract-pharma.html This report explores present and future strategies within the contract manufacturing, research, and packaging pharmaceuticals industry. The needs, services offered, criteria for selection, and the advantages of outsourcing are discussed. The study also includes the need for project management, market forecasts and a discussion of the market leaders in the industry. Regulatory requirements and current state of the outsourcing market in the pharmaceuticals and biotechnology industry are also portrayed in this report. en Pharmaceutical Companies 2009-10-21 Cutting Edge Information http://www.the-infoshop.com/study/cei102381-phar-merg-acqui.html Pharmaceutical Mergers and Acquisitions guides you to build an M&A plan that focuses on key goals, avoids costly mistakes, and realizes deal potential as quickly as possible. CEI designed this study to identify the primary drivers of M&A activity. Through the input of pharma industry leaders, our study provides solutions to the greatest M&A pitfalls and gives clear, detailed insight of trends in pharmaceutical deals. The result: a roadmap to the M&A landscape. en 2009-10-21 Datamonitor http://www.the-infoshop.com/study/dc102404-colorectal-cancer.html CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there are 77 agents in development for CRC, 4 of which are in late-phase development. Collectively, they are forecast to achieve sales of $1,398m by 2018. en Diabetes 2009-10-20 Datamonitor http://www.the-infoshop.com/study/dc102408-antidiabetic-australia.html Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest growth is expected in the non-insulin market, the insulin market will continue to dominate, generating revenues of $224m 10 years from now. en Cancer 2009-10-19 Frost & Sullivan http://www.the-infoshop.com/study/fs102289-glob-skin-cancer.html This research service analyses the global skin cancer therapeutics market. It analyses market drivers, restraints and challenges faced by industry participants. Revenue forecasts and pipeline analysis has been discussed. It also provides strategic recommendations. en Mental Disease 2009-10-16 Urch Publishing, Ltd. http://www.the-infoshop.com/study/ur102220-addiction-disorder.html The substance dependence field is transforming into a high-growth market opportunity. Supported by the success of Pfizer' s recently launched Chantix/Champix, which is on track for blockbuster status in the smoking cessation sector, pharmacotherapies in development for alcohol, narcotic, and nicotine dependencies are poised to radically change the addiction treatment landscape in this difficult-to-treat patient population. The report estimates that the current market for addiction disorders is valued at US$3.2 billion and this is forecast to increase 19% to US$3.8 billion by 2016. en Generic Drugs 2009-10-15 Espicom Business Intelligence http://www.the-infoshop.com/study/es102251-biosimilars.html The future of the pharmaceutical industry lies with biotechnology. Biotech drugs account for around 10-15% of the current pharmaceutical market, and the sector is outperforming the market as a whole in terms of growth. en 2009-10-15 Datamonitor http://www.the-infoshop.com/study/dc103031-pharmavitae.html This analysis examines the historical and forecast performance for GSK in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en Infection Disease 2009-10-14 France Innovation Scientifique et Transfert (FIST SA) http://www.the-infoshop.com/study/fist102157-hiv-therapy-patent.html The Human Immunodeficiency Virus (HIV) is a double-stranded RNA virus from the Retroviridae family. Discovered in 1983, HIV is responsible for the Acquired Immune Deficiency Syndrome (AIDS). Its mechanisms of action and transmission were described in the years following its discovery, and the first treatment, called azidothymidine or azidovudine, was marketed in 1987 as a monotherapy. en Infection Disease 2009-10-14 France Innovation Scientifique et Transfert (FIST SA) http://www.the-infoshop.com/study/fist102159-malaria-patent.html Malaria, along with HIV and Tuberculosis, is one of the three most common infectious diseases in the world. It has infected human beings for over 50,000 years and may have been a human pathogen throughout the entire history of our species. An estimated 300 million people suffer from this disease and more than one million die each year. en Infection Disease 2009-10-13 Decision Resources, Inc. http://www.the-infoshop.com/study/dr102136-pandemic-paradigm.html WHO and the European Centre for Disease Prevention and Control (ECDC) are advising countries to prepare for a more severe second wave of A/H1N1 2009 in the winter of 2009-2010. This advisement could be warranted, given that no infectious disease has killed more people in a short period of time than infl uenza. en Drug Discovery 2009-10-12 Datamonitor http://www.the-infoshop.com/study/dc102412-rheumatoid-arthritis.html Drugs with new mechanisms, in particular Pfizer' s oral JAK inhibitor CP-690,550 and Chugai/Roche' s Actemra (tocilizumab), will launch for rheumatoid arthritis and should offer advantages over current therapies, but do not come without some safety signals. Late-stage pipeline launches will be a major contributor to market growth from $7.4 billion in 2008 to $11.5 billion in 2018. en Mental Disease 2009-10-08 Datamonitor http://www.the-infoshop.com/study/dc102087-novel-mechanism.html With current blockbuster brands facing generic competition, Datamonitor forecasts the antidepressant market to decline at a compound annual growth rate of -2.0% (20082018). However, an antidepressant with a novel mechanism of action has huge commercial potential and the most promising candidate to date is Servier and Novartis' s melatonin agonist and serotonin antagonist Valdoxan (agomelatine). en Neurodegenerative Disease 2009-10-08 Datamonitor http://www.the-infoshop.com/study/dc102088-parkinsons-disease.html The Parkinson' s disease market is approaching maturity, with the threat of generic incursion evident in each drug class. Although growth will be stifled by generic launches, relatively successful lifecycle management strategies and new product launches see the Parkinson' s disease market grow at a compound annual growth rate (CAGR) of 2.6% over the next 10 years (20082018). en Cancer 2009-10-08 Datamonitor http://www.the-infoshop.com/study/dc102089-acute-leukemias.html The drug therapy of acute myeloid leukemia (AML) and adult acute lymphoblastic leukemia (ALL) is largely based on chemotherapy regimens that have changed little in the past few decades. Patient outcomes for both diseases remain poor, particularly for elderly and high-risk patients. As the limits of cytotoxic chemotherapy are being reached, an unmet need remains for novel, improved therapies. en Neurodegenerative Disease 2009-10-08 Datamonitor http://www.the-infoshop.com/study/dc102090-anticonvulsants.html In 2008, seven major market sales of anticonvulsants reached $13.6 billion, making it one of the largest therapeutic drug classes in the Pharmaceutical sector. However, generic incursion of second generation anticonvulsants will continue to increase the barrier to entry for prospective players, although viable commercial opportunities exist to optimize returns from this lucrative drug class market en Generic Drugs 2009-10-06 Espicom Business Intelligence http://www.the-infoshop.com/study/es101214-glob-generics.html The operating environment for generic companies is changing rapidly as the industry matures and growth focuses on new market opportunities. en Neurodegenerative Disease 2009-10-06 Insight Pharma Reports http://www.the-infoshop.com/study/cd101944-immuno-vaccine.html This report: Covers a wide range of conditions for which immunotherapies may be effective, including Alzheimer' s disease, addiction, other neurological indications, cardiovascular diseases, hematological disorders, ophthalmic diseases, bone metabolism disorders, type 2 diabetes, among others Reviews emerging immunotherapies and vaccines for these indications as well as business considerations for companies active in these markets Includes expert interviews Applications of immunotherapies and vaccines for prevention and treatment of infectious diseases and cancer are well known. en 2009-10-05 BioPharm Reports (Technology and Markets Ltd) http://www.the-infoshop.com/study/bph102131-stroke.html This report presents the findings of a global survey on current treatments and prescribing practices for Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA). These findings were made following the participation of more than 230 clinics worldwide, which provided detailed information on their treatment practices. en Pharmaceutical Companies 2009-10-02 Cutting Edge Information http://www.the-infoshop.com/study/cei101076-pharma-speaker.html The ever-present regulatory scrutiny that the life science industry currently faces has not overlooked speaker events. Soaring healthcare costs and worries about the influence of drug companies on prescribing behavior bring any intersection of the two communities under the harsh glare of inspection. For speaker programs, new regulation limits the measures the pharmaceutical company had at their disposal to entice physicians to attend. en Pharmaceutical Companies 2009-10-02 Datamonitor http://www.the-infoshop.com/study/dc101286-allergan-inc.html This analysis examines the historical and forecast performance for Allergan in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en Pharmaceutical Companies 2009-10-02 Datamonitor http://www.the-infoshop.com/study/dc101287-chugai-pharma.html This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en Infection Disease 2009-10-02 Datamonitor http://www.the-infoshop.com/study/dc101288-hiv.html Three new partnerships are reshaping the competitive environment in HIV. Most notably, Tibotec/Johnson & Johnson is linking up with Gilead to combine their Phase III drug rilpivirine with Truvada to create a new gold standard fixed dose combination for treatment-naive patients. Addressing Atripla' s shortcomings, Datamonitor expects this product to dominate the market. en Drug Discovery 2009-10-02 Datamonitor http://www.the-infoshop.com/study/dc101289-orphan-drug.html With the pharmaceutical industry reducing its focus on the primary care blockbuster model, Big Pharma is now looking towards the development and commercialization of more niche, high value, often biologic therapies, for the treatment of smaller patient populations. en 2009-10-02 Datamonitor http://www.the-infoshop.com/study/dc101290-hormonal-contracept.html Since the 1960s, hormonal contraceptives have been widely used as effective birth control in the developed world. Although they are mainly used to prevent pregnancies, they can be used for treating other conditions such as acne, endometriosis, and polycystic ovarian syndrome. In 2008, the hormonal contraceptives market was worth $6.2 billion across the seven major pharmaceutical countries. en 2009-10-02 Datamonitor http://www.the-infoshop.com/study/dc101940-pharma101.html The life sciences industry is unique and complex. Without having the proper background, it can be difficult for IT vendors to enter this conservative market. Those willing to put in the extra effort to truly understand the pharmaceutical and biotechnology industries will realize there is considerable opportunity for technology. en Veterinary Medicine 2009-10-01 Kalorama Information http://www.the-infoshop.com/study/kl100084-veterinary-diagno.html Diagnostic tests are an essential tool for confirming the health status of animals. The global impact of diseases such as bovine spongiform encephalopathy, foot and mouth disease, and highly pathogenic avian influenza has revealed that diagnostic tests play a key role not only in facilitating safe trade but also in many other areas such as the early detection of new diseases and the control of exotic or enzootic animal diseases. en 2009-10-01 Global Industry Analysts, Inc. http://www.the-infoshop.com/study/go100761-health-spas.html The global outlook series on Health Spas provides a collection of statistical findings, market briefs, and concise summaries of research findings. Market discussions in the report are amply illustrated with 61 fact-rich market data tables, charts, and graphs. en 2009-10-01 Global Industry Analysts, Inc. http://www.the-infoshop.com/study/go100764-life-coaching.html The global outlook series on Life Coaching provides a collection of market briefs, and concise summaries of research findings. The report offers a bird' s eye view of the industry; highlights latest market trends, and demand drivers. Overview of the industry' s most noteworthy regional market, the US, is provided with unbiased research commentary to provide the reader a rudimentary understanding of the prevailing market climate. en Infection Disease 2009-10-01 Trimark Publications http://www.the-infoshop.com/study/tk100904-infec-diseas-drug.html According to the World Health Organization (WHO), six infectious diseases--pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS--account for half of all premature deaths worldwide, killing mostly children and young adults. en Pharmaceutical Companies 2009-10-01 CurrentPartnering, a division of Wildwood Ventures Limited http://www.the-infoshop.com/study/wild101043-drug-delivery-pharma.html The Drug Delivery Partnering Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the drug delivery partnering agreements entered into by the worlds leading healthcare companies. en 2009-10-01 Global Industry Analysts, Inc. http://www.the-infoshop.com/study/go101276-alternative-med.html The global outlook series on Alternative Medicine provides anecdotes, market briefs, and concise summaries of research findings. The report highlights the primary growth drivers, market challenges, and reviews global and regional trends across various segments. Market discussions in the report are amply illustrated with 33 fact-rich market data tables, charts, and graphs.Regional markets briefly abstracted include the United States, Canada, Japan, Europe, the United Kingdom, Denmark, China, India, Taiwan, and Australia. Also included is an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 463 companies worldwide. en 2009-10-01 Kalorama Information http://www.the-infoshop.com/study/kl101994-wellness-programs.html Utilization of wellness programs in the United States has experienced strong recent growth this is expected to continue through the forecast period. As more people participate in wellness programs, their usage of various health care products and services will be affected, as well the revenues of wellness program providers. This report looks at the emerging wellness industry and estimates the market for wellness related products and services. en Infection Disease 2009-10-01 Kalorama Information http://www.the-infoshop.com/study/kl101995-anti-infective.html The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to them. This Kalorama Information The World Market for Anti-Infectives considers the anti-infective drug market as it faces challenges with resistance and generic competition. en 2009-10-01 Business Insights http://www.the-infoshop.com/study/rb103269-oncology-diagnostics.html Despite public policy measures to prevent cancer, such as tobacco control and vaccination against HPV, cancer is sure to remain a significant public health problem throughout the 21st century. Indeed, the global demographic shift towards an ageing population and the spread of high tech modern medicine throughout the emerging economies of Asia and (maybe later) Africa, will expand the market for cancer diagnostics globally. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13856-boehringer.html Pharmaceutical company intelligence reports from Espicom provide a full review of the company' s activities together with five-year sales forecasts for its key products. The company' s financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13872-be-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13876-pt-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13877-my-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13878-mx-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13879-pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13880-ua-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13884-ro-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13889-bd-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13891-serbia-pharm.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13895-it-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13896-ru-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es14573-id-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es15383-il-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es15384-lt-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es15385-pl-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es15386-uk-pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es15736-cz-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es15737-gr-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es15838_solvay.html Pharmaceutical company intelligence reports from Espicom provide a full review of the company' s activities together with five-year sales forecasts for its key products. The company' s financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es15975-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es15976-hk-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es15977-hungary-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es15978-nz-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es16352-ar-pharma-mkt.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es16353-bg-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es16354-ee-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es16925-pharmaceutical-france.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es16926-pharmaceutical-ireland.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es16927-pharma-philippin.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es16928-pharma-vietnam.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es17357-pharma-australia.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es17358-pharma-singapore.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es17359-pharma-africa.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es17360-pharma-sweden.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es17836-pharma-norway.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es17837-pharma-peru.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es17838-tr-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es17839-pharma-usa.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es17860_recordati_pharma.html Pharmaceutical company intelligence reports from Espicom provide a full review of the company' s activities together with five-year sales forecasts for its key products. The company' s financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es18373_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es18375_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es19121_brazil_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es19122-pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es19123-pharma-taiwan.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es19124-pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es19508_egypt_pharma_market.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es19510_pharma_market_finland.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es19512_japan_pharma_company.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es19513_pakistan_pharma_market.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es20113_pharmaceutical_market.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es20114_chile_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es20115_germany_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es20116_latvia_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es20785_austria_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es20787_china_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es20788_saudi_arabia_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es20789_spain_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es22703_cuba_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es22704_denmark_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es22707_switzerland_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/india-pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es32711-pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es41652-pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es46040-pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/annual/es46322-pharmaceuticals.html Each country report in this regional collection provides a comprehensive analysis of the pharmaceutical market, including five-year market forecasts. en 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/annual/es46716-pharmaceuticals.html Each country report in this regional collection provides a comprehensive analysis of the pharmaceutical market, including five-year market forecasts. en 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/annual/es71165-pharmaceuticals.html The countries of Central and Eastern Europe represent a total market of 285 million people and a combined GDP of US$3.3 trillion in 2008. en Regulation 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es97246-pharma-korea.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/annual/es97908-pharma-se-asia.html The eight Asian countries covered in this service represent a total market of 588 million people and a combined GDP of US$2.8 trillion in 2008 en Pharmaceutical Companies 2009-09-30 Business Insights http://www.the-infoshop.com/study/rb100892-counterfeit-p-trade.html Parallel trade is a legitimate method of pharmaceutical import and export within the EU zone. Although previously recognized in North America as illegal, cross-border reimportation is now permitted following legislation allowing drugs to be imported into the US from Canada. en Infection Disease 2009-09-30 Mintel International Group Ltd, http://www.the-infoshop.com/study/mt101101-health-hygiene.html Qualitative research run by Mintel with Toluna shows that, although people claim not to have changed their hygiene habits in the wake of the swine flu publicity, they do appear to be more aware of germs. en 2009-09-30 Frost & Sullivan http://www.the-infoshop.com/study/fs101198-pharma-med-devi.html This research service provides a thorough analysis of various aspects of the healthcare industry in the Central and Eastern Europe (focusing on Poland, the Czech Republic, Slovakia, Hungary and Bulgaria). Originally, the research provides the insight of the impact of socio-economic and political factors on the development of the healthcare industry. en 2009-09-30 Frost & Sullivan http://www.the-infoshop.com/study/fs101201-pharma-med-devi.html This research service provides a thorough analysis of various aspects of the healthcare industry in Russia and some CIS countries (Ukraine, Kazakhstan, Belarus). Originally, the research provides the insight of the impact of socio-economic and political factors on the development of the healthcare industry. en OTC Drug 2009-09-30 Euromonitor International http://www.the-infoshop.com/study/eo102481-analgesics-finland.html This report presents Analgesics in Finland. en OTC Drug 2009-09-30 Euromonitor International http://www.the-infoshop.com/study/eo103404-analgesics-china.html This report presents Analgesics in China. en OTC Drug 2009-09-30 Euromonitor International http://www.the-infoshop.com/study/eo103407-remedies-finland.html This report presents Cough, Cold And Allergy (Hay Fever) Remedies in Finland. en OTC Drug 2009-09-30 Euromonitor International http://www.the-infoshop.com/study/eo103409-remedies-finland.html This report presents Digestive Remedies in Finland. en OTC Drug 2009-09-30 Euromonitor International http://www.the-infoshop.com/study/eo103428-aids-china.html This report presents NRT Smoking Cessation Aids in China. en OTC Drug 2009-09-30 Euromonitor International http://www.the-infoshop.com/study/eo103432-aids-finland.html This report presents NRT Smoking Cessation Aids in Finland. en OTC Drug 2009-09-30 Euromonitor International http://www.the-infoshop.com/study/eo103441-eye-care-finland.html This report presents Eye Care in Finland. en OTC Drug 2009-09-30 Euromonitor International http://www.the-infoshop.com/study/eo103443-treatments-finland.html This report presents Wound Treatments in Finland. en Regulation 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/annual/es104171-west-eu-pharma.html The Outlook for Pharmaceutical Markets in Western Europe is a unique collection of management reports from Espicom Business Intelligence. Each report provides individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually, or as a discounted collection, and prices include 4 completely updated reports sent quarterly, together with a comprehensive statistical appendix. There are over 60 markets covered in the worldwide series. en Regulation 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/annual/es104173-e7-outlook-pharma.html The E7 economies have widely differing healthcare systems and priorities, making a detailed knowledge of the background to the market essential for strategic assessment. E7: The Outlook for Pharmaceuticals provides an individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. en Regulation 2009-09-29 Business Insights http://www.the-infoshop.com/study/rb100891-middle-east-pharma.html The Middle East pharmaceutical market is diverse, with a significant presence of leading global players alongside domestic pharmaceutical companies such as Ibrahim, Bilim and Deva. en 2009-09-28 BCC Research http://www.the-infoshop.com/study/bc100798-gastro-pharma.html This report is designed to be a comprehensive business tool to provide an in-depth look at gastrointestinal disorders. The geographic scope of the report is global with a particular emphasis on the United States. Market data is global. The report provides an overview of the gastrointestinal system; gives a brief explanation of disorders of the gastrointestinal system; cites risk factors, where applicable; cites incidence and mortality; presents current pharmaceutical treatments, market size and market participants in both prescription and OTC arenas; and presents potential treatments in research and development, potential market size, and market participants. This report describes the industry in detail, its relationship to the healthcare industry, its participants, and its trends for the future. en 2009-09-25 Decision Resources, Inc. http://www.the-infoshop.com/study/dr100760-in-pharma-pricing.html Faced with a dramatic slowdown in sales in mature pharmaceutical markets, multinational pharmaceutical companies are looking to substantially increase their sales in India and other emerging markets. The Indian market is growing by more than 10% per year, but foreign companies will need to overcome signifi cant obstacles to succeed in a market currently dominated by domestic manufacturers. en Pharmaceutical Companies 2009-09-25 Espicom Business Intelligence http://www.the-infoshop.com/study/es100797-pharma-m-a.html Mergers and, more commonly, acquisitions have long been popular in the pharmaceutical industry. Whether it has been to support flagging drug pipelines, secure IP on promising drug candidates or to quickly access new markets, the industry has for many years been characterised by a vibrant M&A culture. The current recession has, therefore, had a significant impact on the industry' s players, and in more ways than might be immediately obvious. en 2009-09-25 Decision Resources, Inc. http://www.the-infoshop.com/study/dr100808-health-technology.html The use of health technology assessment (HTA) is growing steadily in Europe, and the U.S. government has recently announced $1.1 billion in funding for comparative effectiveness research (CER) as part of its planned overhaul of the U.S. healthcare system. Payers in all markets will increasingly compare new drugs with established therapies and offer the most favorable pricing and reimbursement terms only to drugs that are deemed innovative. en OTC Drug 2009-09-25 Euromonitor International http://www.the-infoshop.com/study/eo101146-sleeping-mexico.html This report presents Calming And Sleeping Products in Mexico. en Generic Drugs 2009-09-24 Markets and Markets http://www.the-infoshop.com/study/mama100546-biosimilars.html The impending expiry of several patented blockbuster biopharmaceuticals and the increasing demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. en 2009-09-24 Frost & Sullivan http://www.the-infoshop.com/study/fs100706-bw-pharma-ind.html This research service presents an in-depth analysis of the Botswana pharmaceutical industry. It provides a general insight into processes of regulations, medical insurance, healthcare procurement and financing. An analysis of key industry dynamics affecting each of pharmaceutical segments is presented, as well as industry sizes and growth rates over the period 2008-2015. In addition, a thorough competitor analysis for each industry was performed. en 2009-09-23 Decision Resources, Inc. http://www.the-infoshop.com/study/dr100642-sarcoidosis-treat.html I' d love there to be a better agent, says a thought leader on the current state of sarcoidosis treatment. Many sarcoidosis patients require little or no treatment, but patients with chronic disease need a therapy that is safer than the corticosteroids that have become the mainstay treatment for the disease. Because substantial market constraints have limited development in this therapeutic area, only a few novel agents are in the pipeline. However, opportunity remains for an agent that can address some of the unmet needs in this market. en Cancer 2009-09-22 Datamonitor http://www.the-infoshop.com/study/dc100878-cytotoxic-a-patent-cliff.html The cancer therapies market offers a high level of commercial reward to a handful of companies including Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly. Cancer therapy sales totaled over $38 billion in the seven major pharmaceutical markets in 2008, growing at a CAGR of 17.4% between 2005 and 2008. en Vaccines 2009-09-18 BCC Research http://www.the-infoshop.com/study/bc100147-dna-vaccine.html The study scope includes DNA vaccine products that are commercial or likely to be commercialized within the next 5 years. Both human and animal health markets are studied. DNA vaccine delivery technologies are also included. DNA vaccine candidates in clinical trials are examined by indication, and future market growth from 2009 through 2014 is estimated. en Drug Discovery 2009-09-18 Decision Resources, Inc. http://www.the-infoshop.com/study/dr100337-pharma-rd.html Can radical changes to the structures and strategies of pharmaceutical R&D operations - such as creating more entrepreneurial environments modeled upon biotech companies - increase their productivity? Many major companies are reorganizing the research branches of their businesses and fi nding creative ways to partner with biotech companies and with each other to access or acquire promising technologies and pipelines. Their goal is to reinvigorate R&D and combat the effects of patent expirations, generics competition, and other industry pressures. en 2009-09-18 Frost & Sullivan http://www.the-infoshop.com/study/fs100429-pharma-ingredi.html This study provides an overview of the global active pharmaceutical ingredients market. It is broadly divided into three chapters- API market analysis, therapeutic-area wise analysis and recommendations to market participants. en Neurodegenerative Disease 2009-09-18 Visiongain http://www.the-infoshop.com/study/kt102656-neurodegenerative.html Rising neurodegenerative disease prevalence and expanding patent populations - where are the best opportunities and how can you unlock these? Our new report - World Neurodegenerative Diseases Market 2009-2024 - explains. en OTC Drug 2009-09-17 Euromonitor International http://www.the-infoshop.com/study/eo100286-cn-otc-healthc.html OTC healthcare continued its healthy growth in 2008, mainly due to rising disposable income levels and growing health awareness among consumers. Robust economic development in China underpinned improving living standards, which enabled consumers to spend more on OTC healthcare. Meanwhile, consumers also became more educated about personal wellbeing via conventional mass media such as TV and newspapers as well as via emerging new media channels such as the internet. OTC healthcare manufacturers also played an important role in consumer education during the review period. Consequently, consumers gained more confidence in self-medication, leading to stronger sales of OTC healthcare. en Pharmaceutical Companies 2009-09-16 Datamonitor http://www.the-infoshop.com/study/dc100995-novo-nordisk.html This analysis examines the historical and forecast performance for Novo Nordisk in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en Pharmaceutical Companies 2009-09-16 Datamonitor http://www.the-infoshop.com/study/dc100996-gilead-sciences.html This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en 2009-09-15 Decision Resources, Inc. http://www.the-infoshop.com/study/dr100333-biopharma-ind.html The biotechnology and pharmaceutical sectors as we know them will soon cease to exist. Companies in these sectors have come face-to-face with the harrowing ordeals of a global recession. Four stresses on the industry are rapidly depleting cash reserves, changing sources of growth, the specter of comparative effectiveness, and the threat posed by biosimilars. Staying alive in the short term and creating a more viable way of doing business are serious concerns. Many biotech companies have put themselves on ice with skeleton staffs in an attempt to ride out the recession, but they may never recover their scientifi c momentum. Mid-tier pharmaceutical companies are scrambling and fear for their independence. A new world order is on the horizon that will be a more unifi ed biopharmaceutical industry. This report addresses the issues underlying the evolving nature of the biotech and mid-tier pharmaceutical sectors and identifi es strategies and opportunities for moving forward. en 2009-09-15 Decision Resources, Inc. http://www.the-infoshop.com/study/dr100335-compani-diagno.html Some naysayers disagree, but we regard companion diagnostics as a win-win scenario for all stakeholders. Companion diagnostics combines drug and diagnostic test development. The potential for effi cient drug development is huge because companion diagnostics can be used to predict drug response and treatment effi cacy - therefore, companion diagnostics are also the perfect means to fulfi llment of the promise of personalized medicine. But the advantages of companion diagnostics are only one side of the equation: they are also seen as disruptors of the pharmaceutical market that could restrict the size of treatable populations. Bringing the differing viewpoints together to form a unifi ed idea of what companion diagnostics really mean to the industry is a challenge, but one that companies must heed because companion diagnostics are making their mark - like it or not. en Pharmaceutical Companies 2009-09-14 Datamonitor http://www.the-infoshop.com/study/dc101002-astrazeneca.html This analysis examines the historical and forecast performance for AstraZeneca in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en Pharmaceutical Companies 2009-09-14 Datamonitor http://www.the-infoshop.com/study/dc101004-pharmavitae.html This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en Pharmaceutical Companies 2009-09-10 La Merie http://www.the-infoshop.com/study/lmer100177-egf-r-agonists.html The present Competitive Intelligence Report about EGF-R agonists and antagonists provides a competitor evaluation in the field of epidermal growth factor receptor (EGF-R; ErbB1) targeting molecules for wound healing or treatment of cancer as of September 2009. en Regulation 2009-09-10 Decision Resources, Inc. http://www.the-infoshop.com/study/dr100334-us-healthc-reform.html The stakes have never been higher or more serious for the pharmaceutical industry - a perfect storm of legislation is moving through Washington, D.C., to address patent reform, healthcare reform, drug importation, authorized generics, biosimilars, and much more. Does the 111th U.S. Congress have the political will to fundamentally change the status quo? One certainty in these uncertain times is that legislation that goes off the table this year is more than likely to resurface next year and the years after that. In this report, we discuss several of the legislative bills of 2009 and the potential impact they could have on the biopharmaceutical industry. en 2009-09-09 Markets and Markets http://www.the-infoshop.com/study/mama99907-autoimm-treat.html The drugs market is estimated to have a revenue of $24.38 billion in 2009, and it is growing with a CAGR of 12.5% from 2009 to 2014. The total services market with therapy and monitoring and drug development as the largest contributor is estimated to be at $9.31 billion in 2009 and it is growing at a CAGR of 14% from 2009 to 2014. Scope of the Report The report provides market overviews and forecasts as well as market drivers and restraints for the global autoimmune treatment market. In addition, it profiles the top forty market players and their respective autoimmune en 2009-09-09 RNCOS E-Services Pvt. Ltd. http://www.the-infoshop.com/study/rnc99934-my-med-tourism.html Malaysia Medical Tourism Outlook 2012 provides thorough analysis of the current market performance and the future outlook of Malaysia' s medical tourism industry. It acknowledges the fact that Malaysia differs vastly from other destinations in terms of cost, infrastructure, human resources, patient perceptions, competencies, and the level of government support. All these factors have been thoroughly studied in the report. In all, the report provides valuable information to clients looking to venture into these markets and helps them to devise strategies while going for an investment/partnership in Malaysia.